Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Logic receives milestone payment from Pfizer
The new use for the unapproved drug candidate was discovered by Gene Logic’s drug repositioning division. Under its drug repositioning agreement with Pfizer, Gene Logic has been seeking
The new use for the unapproved drug candidate was discovered by Gene Logic’s drug repositioning division. Under its drug repositioning agreement with Pfizer, Gene Logic has been seeking
According to Rosetta, recent studies have revealed key roles of microRNAs as regulators of growth, development, function and responses to stress in the heart. The company said that
The alliance will develop antibodies that bind to amyloid beta, a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimer’s patients. Neurimmune will conduct
The company said that it will receive $25 million in gross proceeds from the sale of 4,943,154 shares of its common stock and the issuance of seven-year warrants
The kit, which monitors the viral load of infected patients, is now available to doctors in Canada to help them determine the success of a treatment. The ready-to-use
As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for
The primary objective of Hana’s Phase II study is to assess the efficacy of Marqibo as determined by response rates in patients with uveal melanoma. Secondary objectives are
Exelixis has the option to sell its remaining interest to Taconic, and Taconic also has an option to purchase Exelixis’s remaining interest during certain times and under certain
Under this agreement, IGI grants DermWorx the exclusive rights to market and sell the product in North, Central and South America, the UK and Japan. To maintain exclusivity,
With the completion of the spin off of the immunotherapy business, including its listeria and KBMA platform technologies, Cerus is now solely focused on commercializing the Intercept Blood